CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2025 Top Employers Survey for the eleventh consecutive year. Moderna was recognized for its commitment to continuous innovation and a culture that reflects the values of its employees. ...

Moderna, Inc. (NASDAQ:MRNA) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company’s investigational cytomegalovirus (CMV) vaccine. CMV is a herpes virus. Those who are pregnant or have compromised immune systems are most at risk from CMV.The study did not meet its primary efficacy endpoint of preventing CMV infection in seronegative female participants of childbearing age (16-40 years of age).Moderna will discontinue its congenital CMV clinical developm ...

BREAKING: Crude Oil Jumps 5% On Trump MoveModerna (MRNA) stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women.The study's goal was to prevent cytomegalovirus from taking hold in study volunteers. CMV is a common virus and is generally harmless, but it can be a concern during pregnancy. A pregnant woman can pass the virus to the fetus, leading to congenital CMV. This can cause birth defects or long-term problems.Participants received shots at da ...

Core Insights - Moderna, Inc. will host its Investor Event - Analyst Day on November 20, 2025, at 9:00 a.m. ET [1] Company Information - The event is aimed at providing insights and updates to investors regarding the company's strategies and future directions [1]

Valued at $10.7 billion by market cap, Moderna, Inc. (MRNA) is a biotechnology company specializing in the development and commercialization of messenger RNA (mRNA) therapeutics and vaccines. The Cambridge, Massachusetts-based company is best known for its COVID-19 vaccine (mRNA-1273, branded as Spikevax), which was one of the first mRNA vaccines authorized for emergency use globally. The healthcare major is expected to announce its third-quarter results on Thursday, Nov. 6. Ahead of the event, analysts e ...

每经AI快讯，10月23日，Moderna盘前跌超4%，此前该公司因试验受挫而暂停开发预防出生缺陷的疫 苗。 ...

这项关键试验涉及约7,500名16-40岁女性，来自13个国家约300个研究中心，结果显示疫苗对原发性 CMV感染的有效率仅为6%至23%，远低于公司的目标。 | MRNA Moderna | | | | --- | --- | --- | | 26.850 + -0.640 -2.33% | | 收盘价 10/22 15:59 美东 | | 25.770 + -1.080 -4.02% | | 盘前价 10/23 04:18 美东 | | 二 24 4 4 S S 8 同 ♥ 自选 | | ● 快捷交易 | | 最高价 27.350 | 开盘价 27.210 | 成交量 787.17万 | | 最低价 26.265 | 昨收价 27.490 | 成交额 2.1亿 | | 平均价 26.641 | 市盈率TM 亏损 | 总市值 104.87亿 … | | 振 幅 3.95% | 市盈率(静) 亏损 | 总股本 3.91亿 | | 换手率 2.16% | 市净率 1.115 | 流通值 97.94亿 | | 52周最高 57.690 | 委 比 36.99% | 流通股 3.65亿 | | 52周最低 23.1 ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. If the Commonwealth of Massachusetts is a canary in the coal mine for the shape of the U.S. biotech industry, then hold onto your hats. Long home to some of the most concentrated and prolific hubs of biotech R&D, Massachusetts is witnessing a painful downturn in pipeline growth, venture funding, federal support and sector employment, according to a report from indust ...

格隆汇10月23日｜华尔街投行Leerink Partners将Moderna目标价从16美元下调至12美元。 ...

Moderna said on Wednesday it will discontinue development of its experimental vaccine to prevent cytomegalovirus, a common cause of birth defects, after it failed to meet the main goal of a late-stage... ...